Tempest Therapeutics, Inc.: net property, plant and equipment
Net property, plant and equipment for Tempest Therapeutics, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Tempest Therapeutics, Inc. financial histories
What this measure means
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
Exact concept: us-gaap:PropertyPlantAndEquipmentNet. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2012-12-31 to 2025-12-31. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2025-12-31 | 605,000 | USD | 2026-03-30 | 10-K · 0001193125-26-130490 |
| At date | 2024-12-31 | 886,000 | USD | 2026-03-30 | 10-K · 0001193125-26-130490 |
| At date | 2023-12-31 | 840,000 | USD | 2025-03-27 | 10-K · 0000950170-25-046144 |
| At date | 2022-12-31 | 1,060,000 | USD | 2024-03-19 | 10-K · 0000950170-24-033555 |
| At date | 2021-12-31 | 1,113,000 | USD | 2023-03-22 | 10-K · 0000950170-23-009237 |
| At date | 2020-12-31 | 1,110,000 | USD | 2022-03-29 | 10-K · 0001628280-22-007717 |
| At date | 2017-12-31 | 3,113,000 | USD | 2018-03-15 | 10-K · 0001544227-18-000002 |
| At date | 2016-12-31 | 5,572,000 | USD | 2018-03-15 | 10-K · 0001544227-18-000002 |
| At date | 2015-12-31 | 8,313,000 | USD | 2017-03-02 | 10-K · 0001544227-17-000002 |
| At date | 2014-12-31 | 3,367,000 | USD | 2016-02-26 | 10-K · 0001544227-16-000008 |
| At date | 2013-12-31 | 880,000 | USD | 2015-03-16 | 10-K · 0001047469-15-002286 |
| At date | 2012-12-31 | 756,000 | USD | 2014-02-27 | 10-K · 0001047469-14-001433 |
Related financial histories
- Tempest Therapeutics, Inc.: total assets
- Tempest Therapeutics, Inc.: total liabilities
- Tempest Therapeutics, Inc.: stockholders equity
- Tempest Therapeutics, Inc.: cash and cash equivalents
- Tempest Therapeutics, Inc.: net income or loss
- Tempest Therapeutics, Inc.: operating cash flow
- Tempest Therapeutics, Inc.: capital expenditure payments
- Tempest Therapeutics, Inc.: revenue
- Tempest Therapeutics, Inc.: financing cash flow
- Tempest Therapeutics, Inc.: investing cash flow
- Tempest Therapeutics, Inc.: retained earnings or deficit
- Tempest Therapeutics, Inc.: basic weighted-average shares
- Tempest Therapeutics, Inc.: diluted weighted-average shares
- Tempest Therapeutics, Inc.: basic earnings per share
- Tempest Therapeutics, Inc.: diluted earnings per share
- Tempest Therapeutics, Inc.: income tax expense or benefit
- Tempest Therapeutics, Inc.: share-based compensation expense
- Tempest Therapeutics, Inc.: operating income or loss
- Tempest Therapeutics, Inc.: current assets
- Tempest Therapeutics, Inc.: interest expense
- Tempest Therapeutics, Inc.: current liabilities
- Tempest Therapeutics, Inc.: current accounts payable
- Tempest Therapeutics, Inc.: operating expenses
- Tempest Therapeutics, Inc.: cost of revenue
- Tempest Therapeutics, Inc.: selling, general and administrative expense
- Tempest Therapeutics, Inc.: research and development expense
Inspect the source
- Entity
- Tempest Therapeutics, Inc. / CIK 0001544227
- Captured
- 2026-09-20T09:17:51.925Z
- SEC response SHA-256
f683ea551738b82452fd5e2664c193862efb5a386398d7ed12682e2b4be7d091
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001544227.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))